28. Hairy Cell Leukemia

  1. Stefan Faderl MD Associate Professor and
  2. Hagop Kantarjian MD Chairman Professor
  1. Farhad Ravandi MD Associate Professor of Medicine

Published Online: 4 JAN 2011

DOI: 10.1002/9781444327359.ch28

Leukemias: Principles and Practice of Therapy

Leukemias: Principles and Practice of Therapy

How to Cite

Ravandi, F. (2010) Hairy Cell Leukemia, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch28

Editor Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Publication History

  1. Published Online: 4 JAN 2011
  2. Published Print: 26 NOV 2010

ISBN Information

Print ISBN: 9781405182355

Online ISBN: 9781444327359

SEARCH

Keywords:

  • hairy cell leukemia;
  • therapy;
  • pathogenesis

Summary

Over the past five decades, progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease, with the majority of patients achieving complete remissions with the currently available treatment strategies and with survival curves similar to those for appropriate age-matched individuals without the disease. At the same time, new technologies are allowing better understanding of the molecular mechanisms responsible for the pathogenesis of this as well as other indolent lymphoid neoplasms. Several studies, using modern techniques with different sensitivities, have demonstrated the persistence of minimal residual disease (MRD) after therapy with nucleoside analogs in the majority of patients. However, it is not clear whether such MRD would invariably lead to leukemia recurrence or what level of MRD can predict relapse. The role of monoclonal antibodies, naked or conjugated with toxins, in the management of HCL and their ability to eradicate MRD is under investigation. Whether such strategies of chemo-immunotherapy would lead to further improvements in the outcome of patients with HCL would need to be further investigated.